Read by QxMD icon Read

neo-adjuvant chemotherapy

John Charlson
Soft tissue sarcoma (STS) is a heterogeneous disease, in terms of histologic subtype, body site of presentation, and behavior. Localized soft tissue sarcoma may be cured with complete tumor excision, but overall, outcomes are sub-optimal. Metastatic disease is associated with shortened survival. Systemic therapy has been studied for several decades as adjunctive therapy, but the use of adjuvant and neo-adjuvant chemotherapy remains controversial. The heterogeneity of patients included in clinical trials, and of sarcoma in general, has made it difficult to draw conclusions about which patients with localized STS should be treated with chemotherapy...
October 25, 2018: Current Treatment Options in Oncology
F Chamming's, Y Ueno, A Aldis, M Seidler, B Mesurolle, A Omeroglu, B Gallix, C Reinhold
PURPOSE: To evaluate whether enhancement of breast cancer on pre-treatment dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as evaluated semi-quantitatively using computer-aided detection (CAD) is associated with response to neo-adjuvant chemotherapy. MATERIALS AND METHODS: A total of 84 women, (mean age, 51±10 [SD] years; range: 30-73 years) with 84 breast cancers who underwent MRI before neo-adjuvant chemotherapy were included in this retrospective study...
October 22, 2018: Diagnostic and Interventional Imaging
Stephen McCain, James Trainor, Damian T McManus, Úna C McMenamin, Stephen McQuaid, Victoria Bingham, Jacqueline A James, Manuel Salto-Tellez, Richard C Turkington, Helen G Coleman
Aims: Vitamin D receptor (VDR) expression has been associated with survival in several cancer sites. This study aims to evaluate the association between VDR expression and prognosis in oesophageal adenocarcinoma patients. Results: During a median of 2.5 (maximum 9) years of follow-up, 75 patients died. In analysis adjusted for confounders, higher VDR expression was associated with an improved overall survival (HR 0.49 95% CI 0.25-0.96) and disease-specific survival (HR 0...
September 28, 2018: Oncotarget
Jean-Marc Classe, Cecile Loaec, P Gimbergues, S Alran, C Tunon de Lara, P F Dupre, Roman Rouzier, C Faure, N Paillocher, M P Chauvet, G Houvenaeghel, M Gutowski, P De Blay, J L Verhaeghe, E Barranger, C Lefebvre, C Ngo, G Ferron, C Palpacuer, L Campion
PURPOSE: GANEA2 study was designed to assess accuracy and safety of sentinel lymph node (SLN) after neo-adjuvant chemotherapy (NAC) in breast cancer patients. METHODS: Early breast cancer patients treated with NAC were included. Before NAC, patients with cytologically proven node involvement were allocated into the pN1 group, other patient were allocated into the cN0 group. After NAC, pN1 group patients underwent SLN and axillary lymph node dissection (ALND); cN0 group patients underwent SLN and ALND only in case of mapping failure or SLN involvement...
October 20, 2018: Breast Cancer Research and Treatment
Stefanie de Groot, Leoni A Louwé, Ashna Ie Ramautar, Johanneke Ea Portielje, Aernout C Ogilvie, Erdogan Batman, Marta Fiocco, Judith R Kroep
Background: Oocyte and embryo cryopreservation, using controlled ovarian stimulation (COS), are common fertility preservation methodologies in breast cancer patients receiving gonadotoxic neo (adjuvant) chemotherapy (CT). The effects of COS and peak estradiol levels on CT-induced side effects are unknown. Patients and methods: Eighteen patients with stage II and III breast cancer underwent oocyte or embryo cryopreservation at Leiden University Medical Center before receiving docetaxel, adriamycin, and cyclophosphamide (TAC) CT (COS group)...
2018: Cancer Management and Research
K G Foley, A Christian, N Patel, W G Lewis, S A Roberts
PURPOSE: A positive circumferential resection margin (CRM) is regarded as a poor prognostic indicator in oesophageal cancer (OC) but its prediction can be challenging. MRI is used to predict a threatened CRM in rectal cancer but is not commonly performed in OC unlike PET/CT, which is now routinely used. Therefore, this study assessed the additional predictive value of PET-defined tumour variables compared with EUS and CT T-stage. The prognostic significance of CRM status was also assessed...
October 2018: European Journal of Radiology
Asif Saifuddin, Ban Sharif, Craig Gerrand, Jeremy Whelan
Osteosarcoma is the commonest primary malignant bone tumour in children and adolescents, the majority of cases being conventional intra-medullary high-grade tumours affecting the appendicular skeleton. Treatment is typically with a combination of neo-adjuvant chemotherapy, tumour resection with limb reconstruction and post-operative chemotherapy. The current article reviews the role of magnetic resonance imaging (MRI) in the pre-operative assessment of high-grade central conventional osteosarcoma.
October 4, 2018: Skeletal Radiology
Juhi Agrawal, Sandeep Mehta, Ashish Goel, Veda Padmapriya Selvakumar, Kapil Kumar, Pankaj Kumar Pande
Breast conservation therapy (BCT) is now internationally accepted treatment for early breast cancer. Despite of high incidence of carcinoma breast in India, BCT rates are very low as compared to the west. In this article, we wish to share our experience of breast conservation with oncoplasty in Indian women. A retrospective analysis of case records of patients treated with oncoplastic breast conservation from January 2009 to June 2014 in a single surgical oncology unit in a tertiary cancer institute. Demographic patient data, stage of disease, location of primary tumour, use of neo-adjuvant chemotherapy if received, tumour size and breast size ratio, reconstruction method used, post-operative complications and aesthetic score of patients were analysed...
September 2018: Indian Journal of Surgical Oncology
Chinmaya Dash, Skanda Moorthy, Kanwaljeet Garg, Pankaj Kumar Singh, Amandeep Kumar, Hitesh Gurjar, P Sarat Chandra, Sasank Sarad Kale
PURPOSE: Choroid plexus tumors (CPT) are rare tumors characterized by papillary and intraventricular growth. The young age of presentation of such tumors, especially in infants as well as the lack of consensus on adjuvant therapy in case of aCPP and CPC create dilemma for the management of such tumors. We discuss the presentation, management, complications and outcome in 15 patients (children <=4 years) and review pertinent literature METHODS: We retrospectively analyzed the case records of all patients with choroid plexus tumors who were operated in our institute from January 2010 to March 2018...
September 24, 2018: World Neurosurgery
Adam Currey, Caitlin R Patten, Carmen Bergom, J Frank Wilson, Amanda L Kong
Preoperative or neo-adjuvant chemotherapy in the management of breast cancer is a treatment approach that has gained in popularity in recent years. However, it is unclear if the treatment paradigms often employed for patients treated with surgery first hold true for those treated with preoperative chemotherapy. The role of sentinel node biopsy and the data supporting its use is different for those with clinically negative and clinically positive nodes prior to chemotherapy. For clinically node-negative patients, sentinel node biopsy after neo-adjuvant chemotherapy may be appropriate...
September 25, 2018: Breast Journal
Katharina Smetanay, Philippe Junio, Manuel Feißt, Julia Seitz, Jessica Cecile Hassel, Luisa Mayer, Lina Maria Matthies, Arina Schumann, André Hennigs, Jörg Heil, Christof Sohn, Dirk Jaeger, Andreas Schneeweiss, Frederik Marmé
PURPOSE: Chemotherapy-induced alopecia (CIA) is a distressing side effect for women with breast cancer undergoing chemotherapy. Scalp cooling is a method aiming to prevent CIA, but its efficacy is not well defined. Randomized trials until recently and at the time this trial was designed have been lacking. METHODS: Patients undergoing (neo)adjuvant chemotherapy for early breast cancer (EBC) were randomized to scalp cooling (CAP) or observation (NoCAP). All patients received 18-24 weeks of anthracycline- and/or taxane-based chemotherapy...
September 25, 2018: Breast Cancer Research and Treatment
André Wirries, Samir Jabari, Esther P Jansen, Silvia Roth, Elizabeth Figueroa-Juárez, Thaddeus T Wissniowski, Daniel Neureiter, Eckhard Klieser, Philipp Lechler, Steffen Ruchholtz, Detlef K Bartsch, Christoph K Boese, Pietro Di Fazio
Osteosarcoma is an aggressive cancer with a poor long term prognosis. Neo-adjuvant poly-chemotherapy followed by surgical resection remains the standard treatment, which is restricted by multi-drug resistance. If first-line therapy fails, disease control and patient survival rate drop dramatically. We aimed to identify alternative apoptotic mechanisms induced by the histone deacetylase inhibitor panobinostat in osteosarcoma cells. Saos-2, MG63 and U2-OS osteosarcoma cell lines, the immortalized human osteoblast line hFOB and the mouse embryo osteoblasts (MC3T3-E1) were treated with panobinostat...
August 31, 2018: Oncotarget
Miek C Jong, Inge Boers, Arjan P Schouten van der Velden, Suzan van der Meij, Emine Göker, Anja N J H Timmer-Bonte, Herman A van Wietmarschen
OBJECTIVES: To compare the effectiveness of yoga added to standard care (SC) versus SC only, in women with breast cancer during chemotherapy. DESIGN: A multicenter pragmatic, randomized controlled study. SETTINGS/LOCATION: Three hospitals in the Netherlands. SUBJECTS: Women with stage I-III breast cancer undergoing chemotherapy. INTERVENTIONS: Women were randomized either to a program based on Dru Yoga, once a week yoga sessions for 12 weeks (N = 47), or SC only (N = 36)...
September 2018: Journal of Alternative and Complementary Medicine: Research on Paradigm, Practice, and Policy
Hiroji Iwata, Norikazu Masuda, Yutaka Yamamoto, Tomomi Fujisawa, Tatsuya Toyama, Masahiro Kashiwaba, Shoichiro Ohtani, Naruto Taira, Takehiko Sakai, Yoshie Hasegawa, Rikiya Nakamura, Hiromitsu Akabane, Yukiko Shibahara, Hironobu Sasano, Takuhiro Yamaguchi, Kentaro Sakamaki, Helen Bailey, Diana B Cherbavaz, Debbie M Jakubowski, Naoko Sugiyama, Calvin Chao, Yasuo Ohashi
PURPOSE: The Recurrence Score test is validated to predict benefit of adjuvant chemotherapy. TransNEOS, a translational study of New Primary Endocrine-therapy Origination Study (NEOS), evaluated whether Recurrence Score results can predict clinical response to neoadjuvant letrozole. METHODS: NEOS is a phase 3 clinical trial of hormonal therapy ± adjuvant chemotherapy for postmenopausal patients with ER+, HER2-negative, clinically node-negative breast cancer, after six months of neoadjuvant letrozole and breast surgery...
September 21, 2018: Breast Cancer Research and Treatment
Gun Min Kim, Joo Hoon Kim, Ji Heung Jeong, Young Up Cho, Seung Il Kim, Seho Park, Hyung Seok Park, Ji Ye Kim, Joohyuk Sohn
Purpose: Dose-dense chemotherapy (DD-CT) is a preferred (neo) adjuvant regimen in early breast cancer (BC). Although the results of reported randomized trials are conflicting, a recent meta-analysis showed improved overall and disease-free survival with DD-CT compared to conventional schedules. However, no DD-CT safety data for Korean BC patients are available. This phase II study was conducted to evaluate the safety and efficacy of pegteograstim in Korean BC patients receiving DD-CT...
September 19, 2018: Cancer Research and Treatment: Official Journal of Korean Cancer Association
S M Azeem Mohiyuddin, Pooja Harsha, Shreeharsha Maruvala, K R Sumanth, T N Suresh, G N Manjunath, A Sagayaraj, Kouser Mohammadi, A Prashanth Babu, R P Deo
Locally advanced oral cancers extending to infratemporal fossa (ITF) are a challenge to head and neck surgeons. These tumors are classified as T4b whenever the masticator space (MS), pterygoid muscles (PM), and pterygoid plates (PP) are involved according to AJCC classification. Until recently, these tumors were considered inoperable and treated only with palliative intent. However, a few studies in the last decade showed that many of these tumors could be resected with a reasonably favorable prognosis by compartment resection of ITF, particularly when the tumor was below sigmoid notch of mandible...
November 2018: European Archives of Oto-rhino-laryngology
Martin David Forster, Michael-John Devlin
Head and Neck Squamous Cell Carcinoma (HNSCC) is the 6th most common cancer globally and commonly presents with locally advanced disease, which has a recurrence rate of around 50% despite aggressive multi-modality treatment involving surgery, radiotherapy and chemotherapy or EGFR inhibition where appropriate. As understanding of the underlying cancer biology and the complex interactions within the tumor microenvironment improves, there is gathering interest in and evidence for the role of immunomodulating agents in the management of HNSCC...
2018: Frontiers in Oncology
Danijela Golo, Jasna But-Hadzic, Franc Anderluh, Erik Brecelj, Ibrahim Edhemovic, Ana Jeromen, Mirko Omejc, Irena Oblak, Ajra Secerov-Ermenc, Vaneja Velenik
Background The purpose of the study was to improve treatment efficacy for locally advanced rectal cancer (LARC) by shifting half of adjuvant chemotherapy preoperatively to one induction and two consolidation cycles. Patients and methods Between October 2011 and April 2013, 66 patients with LARC were treated with one induction chemotherapy cycle followed by chemoradiotherapy (CRT), two consolidation cycles, surgery and three adjuvant capecitabine cycles. Radiation doses were 50.4 Gy for T2-3 and 54 Gy for T4 tumours in 1...
September 11, 2018: Radiology and Oncology
Claudio Fiorino, Calogero Gumina, Paolo Passoni, Anna Palmisano, Sara Broggi, Giovanni M Cattaneo, Alessandra Di Chiara, Antonio Esposito, Martina Mori, Roberta Raso, Monica Ronzoni, Riccardo Rosati, Najla Slim, Francesco De Cobelli, Riccardo Calandrino, Nadia G Di Muzio
PURPOSE: Introducing a radiobiological index based on early tumor regression during neo-adjuvant radio-chemotherapy (RCT, including oxaliplatin) of rectal adenocarcinoma and testing its discriminative power in predicting the tumor response. METHODS: Seventy-four patients were treated with Helical Tomotherapy following an adaptive (ART) protocol (41.4 Gy/18 fr, 2.3 Gy/fr) delivering a simultaneous integrated boost on the residual tumor in the last 6 fractions up to 45...
September 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Duniya Mosly, Arran Turnbull, Andrew Sims, Carol Ward, Simon Langdon
Ongoing clinical and research efforts seek to optimise the use of endocrine therapy in the treatment of breast cancer. Accurate biomarkers are needed that predict response for individual patients. The presence of the estrogen receptor (ER) as the direct (for tamoxifen and fulvestrant) or indirect (for aromatase inhibitors) target molecule for endocrine therapy remains the foremost biomarker and determinant of response. However, ER expression only poorly predicts outcome and further indicators of response or resistance are required...
August 30, 2018: World Journal of Experimental Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"